Azzad Asset Management Inc /Adv Crispr Therapeutics Ag Transaction History

Azzad Asset Management Inc /Adv

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Apr 01, 2024	SELL	$43.23 - $73.83 $153,596 - $262,317	-3,553 Closed	0 $0
Q1 2022 Apr 01, 2024	BUY	$53.19 - $79.24 $28,988 - $43,185	545 Added 18.12%	3,553 $223 Million
Q4 2021 Apr 01, 2024	BUY	$70.09 - $111.29 $10,583 - $16,804	151 Added 5.29%	3,008 $228 Million
Q3 2021 Apr 01, 2024	SELL	$110.2 - $156.64 $6,942 - $9,868	-63 Reduced 2.16%	2,857 $320 Million
Q2 2021 Apr 01, 2024	BUY	$100.84 - $161.89 $4,840 - $7,770	48 Added 1.67%	2,920 $473 Million
Q1 2021 Apr 01, 2024	BUY	$110.72 - $210.04 $317,987 - $603,234	2,872 New	2,872 $350 Million

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.2B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.